Form 4: Aclarion CFO Gould Granted 17,000 Stock Options

Aclarion, Inc.'s CFO, Gregory A. Gould, was granted 17,000 stock options with an exercise price of $7.15, vesting over four years.

Summary

• Gregory A. Gould, the Chief Financial Officer (CFO) of Aclarion, Inc. (ACON), was granted 17,000 stock options.
• The transaction date for this grant is reported as September 2, 2025.
• Each stock option has an exercise price of $7.15.
• The options will begin vesting on September 2, 2026, with 25% vesting on that date.
• The remaining 75% of the options will vest in 36 equal monthly installments over the subsequent three years.
• The expiration date for these stock options is September 2, 2035.
• Following this transaction, Gregory A. Gould beneficially owns 17,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (stock option grant). It is generally positive as it aligns management incentives with shareholder interests, but it does not provide new operational or financial performance data to significantly alter sentiment.

Positives

• The grant of stock options aligns the Chief Financial Officer's long-term interests with those of the shareholders, incentivizing performance and value creation.
• The vesting schedule, extending over four years, encourages long-term commitment and retention of key management personnel.

Negatives

• No immediate negative impacts are identified from this routine compensation disclosure.

Future Outlook

The vesting schedule for the stock options, extending over four years, indicates a long-term incentive structure designed to retain the CFO and align their performance with the company's sustained growth and shareholder value creation over the coming years.

Industry Context

The granting of stock options to executive officers is a common practice across various industries, particularly in growth-oriented companies, to attract, retain, and motivate key talent by linking their compensation directly to the company's stock performance.

Comparison to Industry Standards

• The structure of this stock option grant, including the vesting schedule and exercise price, is consistent with typical executive compensation packages observed in the biotechnology and medical device sectors for companies of similar size and stage of development.
• Comparable companies often use similar long-term incentive plans to ensure executive alignment with shareholder interests, though the specific number of options and exercise price would vary based on company valuation, executive role, and market conditions at the time of grant.

Related Party Transactions

• The grant of 17,000 stock options to Gregory A. Gould, the Chief Financial Officer, constitutes a related party transaction as it involves compensation to an executive officer of the company. This is a standard form of executive compensation.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the options incentivize the CFO to improve company performance, leading to stock price appreciation. Minor potential for dilution if options are exercised in the future.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale.
• Management: Provides a significant long-term incentive and aligns personal financial interests with the company's stock performance.

Next Steps

• The stock options will begin to vest on September 2, 2026, with subsequent monthly vesting installments over the following three years.
• The CFO may choose to exercise the vested options at any point before their expiration date of September 2, 2035, subject to company policy and market conditions.

Key Dates

Keywords

Aclarion Inc., ACON, Stock Options, Executive Compensation, CFO, Gregory A. Gould, SEC Form 4, Insider Transaction, Equity Grant